Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China

In this study,we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019(COVID-19)vaccination.The patients were recruited from 41 hospitals across 20 Chinese provinces.The vaccination coverage was approximately 22.4%,and the frequency of total adverse events was 13.3%after the first dose and 9.9%after the second dose.The most frequent adverse reaction within 14 days of the first dose was local pain(5.7%).Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age(odds ratio[OR],1.238;95%confidence interval[CI],1.101-1.391),chronic disease history(OR,1.189;95%CI,1.057-1.337),and cancer relapse(OR,1.398;95%CI,1.233-1.585).Of the unvaccinated patients with breast cancer,54.1%opted to receive COVID-19 vaccines if more data were available.Considering the safety but low vaccination coverage for breast cancer,increased positive attitudes and acceptance toward COVID-19 vaccines are important.